NeoGenomics (NEO) Tops Q4 Earnings Estimates

Core Viewpoint - NeoGenomics reported quarterly earnings of $0.04 per share, exceeding the Zacks Consensus Estimate of $0.02 per share, marking a 100% earnings surprise [1] - The company generated revenues of $172 million for the quarter ended December 2024, slightly missing the Zacks Consensus Estimate by 0.92% [2] Group 1: Earnings Performance - The earnings of $0.04 per share represent an increase from $0.03 per share a year ago [1] - Over the last four quarters, NeoGenomics has surpassed consensus EPS estimates four times [2] - The company had a significant earnings surprise of 400% in the previous quarter, where it reported earnings of $0.05 per share against an expectation of $0.01 [1] Group 2: Revenue Insights - Revenues for the quarter were $172 million, compared to $155.55 million in the same quarter last year [2] - NeoGenomics has topped consensus revenue estimates three times over the last four quarters [2] Group 3: Stock Performance and Outlook - NeoGenomics shares have declined approximately 12.5% since the beginning of the year, contrasting with the S&P 500's gain of 4% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.03 on revenues of $173.67 million, and for the current fiscal year, it is $0.20 on revenues of $738.49 million [7] Group 4: Industry Context - The Medical - Biomedical and Genetics industry, to which NeoGenomics belongs, is currently ranked in the top 27% of over 250 Zacks industries [8] - Historical data indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1 [8]